Literature DB >> 21962934

Evaluation of screening risk and nonrisk patients for methicillin-resistant Staphylococcus aureus on admission in an acute care hospital.

Eilish Creamer1, Sandra Galvin, Anthony Dolan, Orla Sherlock, Borislav D Dimitrov, Deirdre Fitzgerald-Hughes, Toney Thomas, John Walsh, Joan Moore, Edmond G Smyth, Anna C Shore, Derek Sullivan, Peter Kinnevey, Piaras O'Lorcain, Robert Cunney, David C Coleman, Hilary Humphreys.   

Abstract

BACKGROUND: Screening for methicillin-resistant Staphylocccus aureus (MRSA) is advocated as part of control measures, but screening all patients on admission to hospital may not be cost-effective.
OBJECTIVE: Our objective was to evaluate the additional yield of screening all patients on admission compared with only patients with risk factors and to assess cost aspects.
METHODS: A prospective, nonrandomized observational study of screening nonrisk patients ≤72 hours of admission compared with only screening patients with risk factors over 3 years in a tertiary referral hospital was conducted. We also assessed the costs of screening both groups.
RESULTS: A total of 48 of 892 (5%) patients was MRSA positive; 28 of 314 (9%) during year 1, 12 of 257 (5%) during year 2, and 8 of 321 (2%) during year 3. There were significantly fewer MRSA-positive patients among nonrisk compared with MRSA-risk patients: 4 of 340 (1%) versus 44 of 552 (8%), P ≤ .0001, respectively. However, screening nonrisk patients increased the number of screening samples by 62% with a proportionate increase in the costs of screening. A backward stepwise logistic regression model identified age > 70 years, diagnosis of chronic pulmonary disease, previous MRSA infection, and admission to hospital during the previous 18 months as the most important independent predictors to discriminate between MRSA-positive and MRSA-negative patients on admission (94.3% accuracy, P < .001).
CONCLUSION: Screening patients without risk factors increased the number of screenings and costs but resulted in few additional cases being detected. In a hospital where MRSA is endemic, targeted screening of at-risk patients on admission remains the most efficient strategy for the early identification of MRSA-positive patients.
Copyright © 2012 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21962934     DOI: 10.1016/j.ajic.2011.07.008

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  5 in total

1.  Transmission of endemic ST22-MRSA-IV on four acute hospital wards investigated using a combination of spa, dru and pulsed-field gel electrophoresis typing.

Authors:  E Creamer; A C Shore; A S Rossney; A Dolan; O Sherlock; D Fitzgerald-Hughes; D J Sullivan; P M Kinnevey; P O'Lorcain; R Cunney; D C Coleman; H Humphreys
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-21       Impact factor: 3.267

Review 2.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

3.  Development and validation of a time and motion guide to assess the costs of prevention and control interventions for nosocomial infections: A Delphi method among experts.

Authors:  Eric Tchouaket Nguemeleu; Sandra Boivin; Stephanie Robins; Drissa Sia; Kelley Kilpatrick; Sylvain Brousseau; Bruno Dubreuil; Catherine Larouche; Natasha Parisien
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

4.  Impact of different diagnostic technologies for MRSA admission screening in hospitals - a decision tree analysis.

Authors:  Claudia Hübner; Nils-Olaf Hübner; Christian Wegner; Steffen Flessa
Journal:  Antimicrob Resist Infect Control       Date:  2015-12-03       Impact factor: 4.887

5.  Development and external validation of a clinical prediction model for MRSA carriage at hospital admission in Southeast Lower Saxony, Germany.

Authors:  Gabriele Raschpichler; Heike Raupach-Rosin; Manas K Akmatov; Stefanie Castell; Nicole Rübsamen; Birgit Feier; Sebastian Szkopek; Wilfried Bautsch; Rafael Mikolajczyk; André Karch
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.